Tel: + 852 39179825 Fax: +852 39179095

Contact us

research description

His research interest mainly focuses on tumor immunology and immunotherapy. Using DC-based DNA vaccine, his research goal is to understand the underlying mechanisms that the vaccination overcomes tumor induced immunosuppression. In particular, his interests include how tumor reactive T cells from successful therapeutic vaccination could initiate a regression process..

selected Publication


    Zhiwu Tan, Jingying Zhou, Allen K.L. Cheung, Zhe Yu, Ka-Wai Cheung, Jianguo Liang, Haibo Wang, Boon Kiat Lee, Kwan Man, Li Liu, Kwok-Yung Yuen, and Zhiwei Chen,* Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment.  2014 Aug 14. pii: canres.0473.2014.


    Zhou JY, Cheung AKL, Liu HG, Tan ZW, Tang X, Kang YX, et al. Potentiating Functional Antigen-specific CD8(+) T Cell Immunity by a Novel PD1 Isoform-based Fusion DNA Vaccine. Molecular Therapy 2013,21:1445-1455.


    Zhou JY, Cheung AKL, Tan ZW, Wang HB, Yu WB, Du YH, et al. PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8(+) T cells in mice. Journal of Clinical Investigation 2013,123:2629-2642

    Tan ZW, Li JB, Pang RF, He SS, He MZ, Tang SX, et al. Screening and evaluation of thiourea derivatives for their HIV capsid and human cyclophilin A inhibitory activity. Medicinal Chemistry Research 2011,20:314-320.


    Li JB, Tan ZW, Tang SX, Hewlett I, Pang RF, He MZ, et al. Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid. Bioorganic & Medicinal Chemistry 2009,17:3177-3188.